Global Targeted Drugs for Neurodegenerative Diseases Market Growth (Status and Outlook) 2024-2030

Global Targeted Drugs for Neurodegenerative Diseases Market Growth (Status and Outlook) 2024-2030

The global Targeted Drugs for Neurodegenerative Diseases market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Targeted Drugs for Neurodegenerative Diseases Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Neurodegenerative Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Neurodegenerative Diseases sales for 2023 through 2029. With Targeted Drugs for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Neurodegenerative Diseases industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Neurodegenerative Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Neurodegenerative Diseases.

United States market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Targeted Drugs for Neurodegenerative Diseases players cover Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.

Segmentation by Type:
Injection
Oral

Segmentation by Application:
Parkinson's Disease (PD)
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Tardive Dyskinesia (TD)
Multiple Sclerosis (MS)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Injection
Oral

Segmentation by Application:
Parkinson's Disease (PD)
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Tardive Dyskinesia (TD)
Multiple Sclerosis (MS)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Inc.
Eli Lilly
Green Valley
NOVARTIS
Bristol-Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
Teva

Please note: The report will take approximately 2 business days to prepare and deliver.